Erasca (ERAS) Operating Leases (2020 - 2026)
Erasca's (ERAS) quarterly Operating Leases came in at $40.7 million in Q1 2026, down 11.56% YoY from $46.0 million in Q1 2025, and down 3.26% on a QoQ basis from $42.1 million in Q4 2025.
Erasca (ERAS) Operating Leases (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Operating Leases data on file, last reported at $40.7 million in Q1 2026.
- Quarterly Operating Leases fell 11.56% year-over-year to $40.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.7 million (down 11.56% YoY) and the FY2025 annual result came in at $42.1 million, down 10.99% from the prior year.
- Operating Leases declined to $40.7 million in Q1 2026, from $42.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $54.9 million in Q1 2023 to a low of $27.4 million in Q2 2022.
- A 5-year average of $46.5 million and a median of $48.5 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases jumped 1544.9% — and 2026, when it declined 11.56%.
- Tracing ERAS's Operating Leases over 5 years: stood at $53.8 million in 2022, then retreated by 3.54% to $51.9 million in 2023, then decreased by 8.9% to $47.3 million in 2024, then declined by 10.99% to $42.1 million in 2025, then dropped by 3.26% to $40.7 million in 2026.
- The last three Operating Leases figures came in at $40.7 million (Q1 2026), $42.1 million (Q4 2025), and $43.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.27 Mn |
| Mar 31, 2026 | 40.70 Mn |
| Dec 31, 2025 | 42.07 Mn |
| Sep 30, 2025 | 43.41 Mn |
| Jun 30, 2025 | 44.71 Mn |
| Mar 31, 2025 | 46.02 Mn |
| Dec 31, 2024 | 47.27 Mn |
| Sep 30, 2024 | 48.49 Mn |
| Jun 30, 2024 | 49.68 Mn |
| Mar 31, 2024 | 50.81 Mn |
| Dec 31, 2023 | 51.89 Mn |
| Sep 30, 2023 | 52.94 Mn |
| Jun 30, 2023 | 53.97 Mn |
| Mar 31, 2023 | 54.94 Mn |
| Dec 31, 2022 | 53.79 Mn |
| Sep 30, 2022 | 53.43 Mn |
| Jun 30, 2022 | 27.44 Mn |
| Mar 31, 2022 | 29.42 Mn |
| Dec 31, 2021 | 18.51 Mn |
| Sep 30, 2021 | 19.37 Mn |